• Improved quantum state readout for Archer's carbon qubit materials
• Signed collaboration agreement with Emergence Quantum for quantum and electronic devices
• Entered agreement with CSIRO to develop quantum machine learning models for fraud detection

Archer Materials Limited, a quantum technology company, provided its Quarterly Activities Report and Appendix 4C for the quarter ended 31 December 2025. The company made significant progress in its 12CQ quantum technology and Biochip medical diagnostics programs. In the 12CQ project, Archer advanced the readout technology for its carbon-based qubit material, achieved electrical gating of the carbon films, and demonstrated the scalability of its qubit platform by synthesizing the material on a 1-inch silicon wafer. Archer also signed a collaboration agreement with Emergence Quantum to identify graphene and carbon-based technologies for next-generation quantum and electronic devices, and entered an agreement with CSIRO to develop quantum machine learning models for financial fraud detection. In the Biochip program, Archer and its partner IMEC demonstrated that the silicon version of the device met blood potassium accuracy requirements, potentially de-risking the supply chain and accelerating the path to market. The company ended the quarter with a cash balance of $10.3 million, excluding a $2.1 million R&D tax rebate received in January 2026.

Archer expects to continue the development and commercialization of its 12CQ quantum technology and Biochip medical diagnostics programs, with a focus on achieving key milestones in the current financial year.

Archer is well-positioned to advance its technology platforms and strategic partnerships, with the aim of commercializing quantum computing and medical diagnostics solutions across multiple industries.